Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum]

• Main Authors: Cheng SL, Ho ML, Lai YF, Wang HC, Hsu JY, Liu SF, Huang MS, Lee CH, Lin CH, Hang LW, Liu YC, Yang KY, Wang JH
• Format: Article
• Language: English
• Published: Dove Medical Press 2021-02-01
• Series: Drug Design, Development and Therapy
• Subjects: budesonide/formoterol; fluticasone propionate/salmeterol; anti-inflammatory reliever and maintenance; and real-world
• Online Access: https://www.dovepress.com/corrigendum-budesonideformoterol-anti-inflammatory-reliever-and-mainte-peer-reviewed-article-DDDT

Cheng SL, Ho ML, Lai YF, et al. Drug Des Devel Ther. 2020;14:5441–5450.The authors have advised there is an error in the formatting of the paper title on page 5441, the title “Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study” should read “Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β2 Agonist: Real-world Effectiveness in pAtients without optimally Controlled asThma (REACT) Study”.The authors have also advised the affiliation list on page 5441 is incorrect.  Read the original article